Can you provide a brief overview of childhood muscular dystrophy, including its types, clinical presentation, diagnostic workup, and management?

Childhood Muscular Dystrophy: Clinical Overview

Childhood muscular dystrophies are a heterogeneous group of genetic disorders characterized by progressive muscle weakness, with Duchenne muscular dystrophy (DMD) being the most common and severe form, requiring early recognition through elevated creatine kinase screening and prompt genetic testing to enable timely multidisciplinary intervention that can significantly impact morbidity and mortality.

Types of Childhood Muscular Dystrophy

The major forms include:

• Duchenne Muscular Dystrophy (DMD): Most common, X-linked, severe progressive course
• Becker Muscular Dystrophy: Milder dystrophinopathy variant
• Congenital Muscular Dystrophies (CMD): Present within first year of life with hypotonia, contractures, and variable brain/eye involvement 1
• Facioscapulohumeral Dystrophy (FSHD): Can present in childhood with bimodal onset (under 5 years or adolescence), often with non-muscular features 2, 3
• Limb-Girdle Muscular Dystrophies: Various genetic subtypes with proximal weakness patterns 4

Clinical Presentation

Duchenne Muscular Dystrophy - Key Features

When to suspect DMD 5:

• Motor delays: Not walking by 16-18 months
• Gowers' sign: Characteristic rising from floor (especially age <5 years)
• Waddling gait with frequent falls
• Difficulty running and climbing stairs
• Incidental finding: Markedly elevated creatine kinase (often 10-100x normal) 6
• Elevated transaminases (AST/ALT) - critical pitfall: Always check CK before liver biopsy in young males 5

Important caveat: In 91.4% of early childhood DMD cases, the initial trigger is incidental hyperCKemia rather than obvious motor symptoms 6. This underscores the value of CK screening in young boys with any developmental concern.

Neurodevelopmental Features

DMD is not purely a muscle disease 6:

• Language delays: Present in 29.8% of patients
• Cognitive/behavioral issues: Common and require early assessment
• Median age of independent walking: 16 months (14.6% walk after 18 months)

Congenital Muscular Dystrophy Presentation

Distinct from DMD with 1:

• Onset within first year of life
• Hypotonia and multiple contractures from birth
• Spinal stiffness
• Variable brain MRI abnormalities (structural/myelination defects)
• Possible eye abnormalities and intellectual impairment

FSHD in Childhood

Unique presentation pattern 2:

• Bimodal age distribution: Either <5 years OR adolescence
• Early-onset cases (<5 years) frequently present with non-muscular symptoms first:
  • Hearing loss (most common)
  • Visual impairment
  • Developmental/psychiatric issues
• Asymmetric facial, shoulder, and upper arm weakness
• May require nutritional and respiratory support in very early onset
• Correlation: Earlier onset correlates with larger genetic deletions

Diagnostic Workup

Initial Screening

Step 1: Creatine Kinase

• Markedly elevated (typically 10-100x normal in DMD)
• Must be checked before liver biopsy in males with elevated transaminases 5

Confirming DMD Diagnosis 5

Genetic testing is first-line (blood sample):

1. Dystrophin deletion/duplication testing:

   • Multiplex ligation-dependent probe amplification (MLPA) - detects deletions and duplications, covers all exons
   • Detects ~77.8% of DMD mutations 6

2. If deletion/duplication negative: Proceed to dystrophin gene sequencing

   • Identifies point mutations and small insertions/deletions
   • Required for complete characterization

3. Muscle biopsy (when needed):

   • Immunocytochemistry and immunoblotting for dystrophin
   • Shows absent dystrophin protein in DMD
   • Optional if genetic testing is positive, but may help distinguish DMD from milder Becker phenotype 5
   • Always perform genetic testing even if biopsy confirms diagnosis - needed for genetic counseling and mutation-specific therapies 5

Critical point: 99% of DMD cases are confirmed by genetic testing; muscle biopsy is reserved for cases with negative genetic panels but high clinical suspicion 6.

General Muscular Dystrophy Workup

Four key diagnostic features 7:

1. Weakness/wasting of pelvic-femoral and scapular muscles ± cardiac involvement
2. Elevated serum creatine kinase
3. Muscle biopsy showing necrosis and regeneration
4. Molecular genetic assessment (next-generation sequencing)

Management Approach

Immediate Post-Diagnosis Actions 5

• Referral to specialized multidisciplinary neuromuscular center
• Genetic counseling for at-risk female family members (carrier testing, prenatal diagnosis options)
• Family support and connection with patient organizations
• Initiate comprehensive monitoring protocols

Multidisciplinary Surveillance for DMD 5

Cardiac monitoring:

• Echocardiogram at diagnosis or by age 6 years
• Every 24 months maximum until age 10, then annually
• Intervene even if asymptomatic - cardiac problems increase with age
• Use standard heart failure medications when function deteriorates

Respiratory management:

• Progressive monitoring as disease advances
• Anticipate need for ventilatory support

Orthopedic/Rehabilitation 5:

• Preventive measures to maintain muscle extensibility and minimize contractures
• Range of motion assessments (goniometry)
• Appropriate exercise/activity encouragement
• Adaptive devices as needed
• Surgical options for tendo-Achilles contractures in select cases

Nutritional/GI monitoring 5:

• Monitor weight gain for age
• Assess for over/underweight
• Screen for dysphagia

Neurodevelopmental support 5:

• Early assessment and intervention for learning, behavior, development
• Promote independence and social development
• Transition planning to adult services

Functional Assessments 5

Ambulatory phase:

• Strength testing every 6 months (manual muscle testing, quantitative myometry)
• Timed function tests
• Range of motion monitoring (identify emerging contractures early)
• Activities of daily living assessments

Non-ambulatory phase:

• Continue upper extremity strength monitoring
• Focus on maintaining function and quality of life

Pharmacological Management

Glucocorticoids remain standard of care for DMD 5, 8:

• Prolong ambulation
• Improve respiratory and cardiac function
• Delay scoliosis

Emerging therapies 8:

• Mutation-specific exon-skipping therapies
• Nonsense mutation readthrough agents
• Gene therapy approaches (recently FDA-approved options available)
• No current therapy restores full-length dystrophin or completely halts progression

Common Pitfalls to Avoid

1. Ordering liver biopsy before checking CK in males with elevated transaminases - DMD must be excluded first 5

2. Assuming normal exam rules out DMD in young children - suspicion cannot be completely excluded by normal muscle exam in children <5 years 5

3. Delaying genetic testing - prolonged diagnostic delays are common, particularly in FSHD 2

4. Missing neurodevelopmental features - language delays and behavioral issues are integral to DMD, not secondary complications 6

5. Failing to screen for cardiac disease in asymptomatic patients - cardiac intervention is needed even without symptoms 5

6. Overlooking non-muscular presentations in early FSHD - hearing loss and visual problems may precede obvious weakness 2

7. Not performing genetic testing after muscle biopsy diagnosis - essential for family counseling and accessing mutation-specific therapies 5